Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 9/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | TEC | P42680 | 1/20 | 0.31 |
| ▸ | TXK | P42681 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008656 | 0.90 | BTK (0.32) | MAPK1JAK2JAK1JAK3CCNC | |
| SCHEMBL29333551 | 0.90 | BTK (0.32) | MAPK1JAK2JAK1JAK3CCNC | |
| SCHEMBL29334426 | 0.87 | KRAS (0.34) | JAK2JAK1JAK3KRASBTK | |
| SCHEMBL29333578 | 0.87 | MAPK1 (0.35) | MAPK1KRASCCNCCDK8 | |
| SCHEMBL29333557 | 0.86 | EGFR (0.32) | CCNCCDK8RIPK1EGFR | |
| SCHEMBL31008595 | 0.86 | EGFR (0.32) | CCNCCDK8RIPK1EGFR | |
| SCHEMBL31008588 | 0.86 | JAK2 (0.35) | MAPK1JAK2JAK1JAK3KRAS | |
| SCHEMBL29333491 | 0.86 | JAK2 (0.35) | MAPK1JAK2JAK1JAK3KRAS | |
| SCHEMBL29334354 | 0.84 | CCNC (0.38) | MAPK1JAK3CCNCCDK8BTK | |
| SCHEMBL29333623 | 0.83 | TEC (0.34) | KRASBTKTECTXKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | MAPK1 1406/4885JAK2 1725/4885JAK1 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.